KPV Peptide Therapy in Philadelphia
Medically reviewed by Charlie Seltzer, MD, CSCS · Updated October 2026
KPV is a tiny anti-inflammatory peptide studied for gut and skin health. It's taken by mouth or applied to the skin, with no injections, and Dr. Seltzer can now prescribe it, compounded to pharmacy standards.
What is KPV?
KPV is just three amino acids long: lysine, proline and valine. It comes from the tail end of alpha-MSH, a natural hormone your body uses to calm inflammation. In lab research, KPV appears to enter inflamed cells and dial down the signals that keep inflammation going.
Fun fact: Alpha-MSH, KPV's parent hormone, is best known as the hormone that tans your skin. KPV keeps the anti-inflammatory part and leaves the tan behind.
What KPV is used for
- Gut inflammation: colitis, IBD symptoms, bloating
- Inflammatory skin conditions: eczema, psoriasis, irritated skin
- Wound healing
- General anti-inflammatory support
What the research actually shows
| Evidence | What exists |
|---|---|
| Lab and animal studies | Oral KPV reduced colitis in mouse models; cell studies show it calms inflammatory signaling |
| Human studies | None published yet |
| FDA status | Not FDA-approved. Available through licensed compounding under HHS's October 2026 enforcement policy, oral and topical only |
Bottom line: promising lab and animal results, no human trials yet. Because it's oral or topical, it avoids the injection-related concerns some other peptides carry.
One lab study on donor skin found topical KPV doesn't pass through the skin easily. FDA's reviewers noted that this could limit whole-body exposure from topical use. HHS described the open safety questions as "an absence of information rather than an observed signal."
KPV and BPC-157 for gut health
KPV is often discussed alongside BPC-157 for gut issues. BPC-157 is studied for repairing the gut lining; KPV is studied for calming the inflammation that damages it. Under federal rules they're prescribed as separate products. Learn about BPC-157 →
Gray market vs. prescribed by Dr. Seltzer
| Online "research" peptides | Dr. Seltzer Lifestyle Medicine | |
|---|---|---|
| Source | Often unknown, frequently overseas | FDA-registered, CGMP ingredient manufacturer |
| Testing | Rarely verified | Identity, purity, potency and contaminant testing |
| Form | Often sold as injectables | Oral or topical, as the federal policy covers |
| Dosing | Forum guesswork | Set by a physician |
| Monitoring | None | Physician follow-up throughout |
How KPV is taken
KPV is compounded as an oral form for gut goals or a topical for skin. Injectable KPV is not covered by the federal policy, and HHS requires documentation that oral forms actually absorb.
Who KPV is right for, and who should avoid it
KPV may fit patients with gut inflammation or inflammatory skin conditions who want a non-injectable option.
It is not recommended if you:
- Are pregnant or breastfeeding
- Are under 18
A doctor who knows both sides
Dr. Charlie Seltzer is a physician, a certified strength and conditioning specialist, and a national-level bodybuilding champion. He looks at gut health as part of the bigger picture of weight, energy and performance.
Also see: BPC-157 · All six peptides
Frequently asked questions
Is KPV legal now?
Yes, when prescribed by a physician and compounded by a licensed pharmacy that meets the HHS quality requirements announced October 28, 2026. It is still not FDA-approved.
Does KPV require injections?
No. Under the federal policy, KPV is compounded only as oral or topical forms.
Will KPV tan my skin?
No. KPV is only the anti-inflammatory end of the tanning hormone, not the part that affects pigment.
Can I take KPV with BPC-157?
Yes, under a physician's care, as separate prescriptions.
Where can I get KPV in Philadelphia?
Dr. Seltzer Lifestyle Medicine, 1429 Walnut Street, Suite 401, in Center City, with virtual visits available.
Start with a consultation
KPV is a compounded drug product and is not FDA-approved. It is available by prescription under the U.S. Department of Health and Human Services' 2026 enforcement discretion policy for 503A compounding. Individual results vary.